The advent of anti-HER2 agents dramatically changed the natural history of HER2-positive
breast cancer. Strong research efforts have brought, starting with trastuzumab, a
class of anti-HER2–targeted therapies, which includes, at present, four approved agents
in the metastatic setting: trastuzumab, lapatinib, pertuzumab and trastuzumab emtansine
(T-DM1). These agents have led to doubling median overall survival (OS), which is
currently longer than 55 months, and more than tripling the 5-year survival rate [
[1]
].Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.N Engl J Med. 2015; 372: 724-734
- Trastuzumab emtansine for HER2-positive advanced breast cancer.N Engl J Med. 2012; 367: 1783-1791
- Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.Lancet Oncol. 2014; 15: 689-699
- Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.Lancet Oncol. 2017; 18: 743-754
- Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: primary results from the KAMILLA study cohort 1.Eur J Cancer. 2019; 109: 92-102
- Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis.J Clin Oncol : Off J Am Soc Clin Oncol. 2014; 32: 2750-2757
- Trastuzumab emtansine for residual invasive HER2-positive breast cancer.N Engl J Med. 2019; 380: 617-628
- Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.Ann Oncol : Off J Eur Soc Med Oncol/ESMO. 2016; 27: 619-624
- Strategies and challenges for the next generation of antibody-drug conjugates.Nat Rev Drug Discov. 2017; 16: 315-337
- The immune system and response to HER2-targeted treatment in breast cancer.Lancet Oncol. 2014; 15: e58-e68
- Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines.Ann Oncol : Off J Eur Soc Med Oncol/ESMO. 2012; 23: 1788-1795
- Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcgamma receptor binding properties.Breast Cancer Res. 2011; 13: R123
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.Nature. 2012; 486: 346-352
- Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis.OncoImmunology. 2017; 6: e1253654
- Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value.Sci Rep. 2017; 7: 11671
- Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.Lancet Oncol. 2017; 18: 52-62
- Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy.Proc Natl Acad Sci U S A. 2011; 108: 7142-7147
- Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade.Sci Transl Med. 2015; 7: 315ra188
- Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.Lancet Oncol. 2019 Mar; 20: 371-382
- p95HER2-T cell bispecific antibody for breast cancer treatment.Sci Transl Med. 2018; 10
- Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3.Sci Transl Med. 2018; 10
- Phase I study of ONT-380, a HER2 inhibitor, in patients with HER2(+)-advanced solid tumors, with an expansion cohort in HER2(+) metastatic breast cancer (MBC).Clin Cancer Res : Off J Am Assoc Cancer Res. 2017; 23: 3529-3536
- Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the NEfERT-T randomized clinical trial.JAMA Oncol. 2016; 2: 1557-1564
Article info
Publication history
Published online: June 20, 2019
Accepted:
April 26,
2019
Received:
April 18,
2019
Identification
Copyright
© 2019 Elsevier Ltd. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1European Journal of CancerVol. 109
- PreviewMany patients with metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) are candidates for trastuzumab emtansine (T-DM1) treatment sometime in their disease history. KAMILLA evaluated safety of T-DM1 in patients with previously treated HER2-positive locally advanced or metastatic BC (advanced BC).
- Full-Text
- Preview
